skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 133,555  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
F42 Exposure response analysis (PKPD) predicts optimal exposure of pridopidine for clinical efficacy of functional capacity
F42 Exposure response analysis (PKPD) predicts optimal exposure of pridopidine for clinical efficacy of functional capacity
Material Type:
Article 		Add to My Research

F42 Exposure response analysis (PKPD) predicts optimal exposure of pridopidine for clinical efficacy of functional capacity

Journal of neurology, neurosurgery and psychiatry, 2021-09, Vol.92 (Suppl 1), p.A36-A36 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0022-3050 ;EISSN: 1468-330X ;DOI: 10.1136/jnnp-2021-EHDN.85

Full text available

Citations Cited by
2
Ustekinumab Dose Intensification Can Be Effective in Crohnʼs Disease Patients Not Responding to Induction: 617
Ustekinumab Dose Intensification Can Be Effective in Crohnʼs Disease Patients Not Responding to Induction: 617
Material Type:
Article 		Add to My Research

Ustekinumab Dose Intensification Can Be Effective in Crohnʼs Disease Patients Not Responding to Induction: 617

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S351-S352 [Peer Reviewed Journal]

Copyright Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins Oct 2018 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/00000434-201810001-00617

Full text available

Citations Cited by
3
0008 Night-Time Administration Of ACT-541468, A Novel Dual Orexin Receptor Antagonist: Characterization Of Its Pharmacokinetics, Next-Day Residual Effects, Safety, And Tolerability
0008 Night-Time Administration Of ACT-541468, A Novel Dual Orexin Receptor Antagonist: Characterization Of Its Pharmacokinetics, Next-Day Residual Effects, Safety, And Tolerability
Material Type:
Article 		Add to My Research

0008 Night-Time Administration Of ACT-541468, A Novel Dual Orexin Receptor Antagonist: Characterization Of Its Pharmacokinetics, Next-Day Residual Effects, Safety, And Tolerability

Sleep (New York, N.Y.), 2018-04, Vol.41 (suppl_1), p.A3-A3 [Peer Reviewed Journal]

Sleep Research Society 2018. Published by Oxford University Press [on behalf of the Sleep Research Society]. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018 ;Copyright © 2018 Sleep Research Society ;ISSN: 0161-8105 ;EISSN: 1550-9109 ;DOI: 10.1093/sleep/zsy061.007

Full text available

Citations Cited by
4
0006 The Pharmacokinetics and Pharmacodynamics of SM-1
0006 The Pharmacokinetics and Pharmacodynamics of SM-1
Material Type:
Article 		Add to My Research

0006 The Pharmacokinetics and Pharmacodynamics of SM-1

Sleep (New York, N.Y.), 2018-04, Vol.41 (suppl_1), p.A2-A3 [Peer Reviewed Journal]

Sleep Research Society 2018. Published by Oxford University Press [on behalf of the Sleep Research Society]. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018 ;Copyright © 2018 Sleep Research Society ;ISSN: 0161-8105 ;EISSN: 1550-9109 ;DOI: 10.1093/sleep/zsy061.005

Full text available

Citations Cited by
5
P155 Use of mycophenolate mofetil and azathioprine in patients with chronic hypersensitivity pneumonitis
P155 Use of mycophenolate mofetil and azathioprine in patients with chronic hypersensitivity pneumonitis
Material Type:
Article 		Add to My Research

P155 Use of mycophenolate mofetil and azathioprine in patients with chronic hypersensitivity pneumonitis

Thorax, 2017-12, Vol.72 (Suppl 3), p.A167 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0040-6376 ;EISSN: 1468-3296 ;DOI: 10.1136/thoraxjnl-2017-210983.297

Full text available

Citations Cited by
6
Optimising the dose and delivery strategies in exercise prescription
Optimising the dose and delivery strategies in exercise prescription
Material Type:
Article 		Add to My Research

Optimising the dose and delivery strategies in exercise prescription

Journal of science and medicine in sport, 2019-10, Vol.22, p.S10-S11 [Peer Reviewed Journal]

2019 ;Copyright Copyright Agency Limited (Distributor) Oct 2019 ;ISSN: 1440-2440 ;EISSN: 1878-1861 ;DOI: 10.1016/j.jsams.2019.08.055

Full text available

Citations Cited by
7
1545 Topiramate is as effective as acetazolamide at lowering intracranial pressure in healthy rodents
1545 Topiramate is as effective as acetazolamide at lowering intracranial pressure in healthy rodents
Material Type:
Article 		Add to My Research

1545 Topiramate is as effective as acetazolamide at lowering intracranial pressure in healthy rodents

Journal of neurology, neurosurgery and psychiatry, 2017-12, Vol.88 (Suppl 1), p.A8-A9 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0022-3050 ;EISSN: 1468-330X ;DOI: 10.1136/jnnp-2017-ABN.24

Full text available

Citations Cited by
8
S700 Early Proactive IFX Dose Optimization Negates the Impact of HLA-DQA105 on Anti-Drug Antibody Formation in Inflammatory Bowel Diseases
S700 Early Proactive IFX Dose Optimization Negates the Impact of HLA-DQA105 on Anti-Drug Antibody Formation in Inflammatory Bowel Diseases
Material Type:
Article 		Add to My Research

S700 Early Proactive IFX Dose Optimization Negates the Impact of HLA-DQA105 on Anti-Drug Antibody Formation in Inflammatory Bowel Diseases

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S317-S318 [Peer Reviewed Journal]

2021 by The American College of Gastroenterology ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/01.ajg.0000776332.13982.cb

Full text available

Citations Cited by
9
F41 The proof-hd phase 3 study: pridopidine’s outcome on function in huntington disease (PROOF)
F41 The proof-hd phase 3 study: pridopidine’s outcome on function in huntington disease (PROOF)
Material Type:
Article 		Add to My Research

F41 The proof-hd phase 3 study: pridopidine’s outcome on function in huntington disease (PROOF)

Journal of neurology, neurosurgery and psychiatry, 2021-09, Vol.92 (Suppl 1), p.A36-A36 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0022-3050 ;EISSN: 1468-330X ;DOI: 10.1136/jnnp-2021-EHDN.84

Full text available

Citations Cited by
10
Delirious episode secondary to rotigotine: the psychotic patch
Delirious episode secondary to rotigotine: the psychotic patch
Material Type:
Article 		Add to My Research

Delirious episode secondary to rotigotine: the psychotic patch

European psychiatry, 2023-03, Vol.66 (S1), p.S626-S626 [Peer Reviewed Journal]

The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association. This work is licensed under the Creative Commons Attribution License This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0924-9338 ;EISSN: 1778-3585 ;DOI: 10.1192/j.eurpsy.2023.1303

Full text available

Citations Cited by
11
Defining the therapeutic reference range for cariprazine
Defining the therapeutic reference range for cariprazine
Material Type:
Article 		Add to My Research

Defining the therapeutic reference range for cariprazine

European psychiatry, 2023-03, Vol.66 (S1), p.S559-S559 [Peer Reviewed Journal]

The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association. This work is licensed under the Creative Commons Attribution License This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0924-9338 ;EISSN: 1778-3585 ;DOI: 10.1192/j.eurpsy.2023.1178

Full text available

Citations Cited by
12
504 Assessment of the Clinical Benefits of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy
504 Assessment of the Clinical Benefits of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy
Material Type:
Article 		Add to My Research

504 Assessment of the Clinical Benefits of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy

Sleep (New York, N.Y.), 2021-05, Vol.44 (Supplement_2), p.A198-A199 [Peer Reviewed Journal]

Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com. ;ISSN: 0161-8105 ;EISSN: 1550-9109 ;DOI: 10.1093/sleep/zsab072.503

Full text available

Citations Cited by
13
P028 Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders
P028 Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders
Material Type:
Article 		Add to My Research

P028 Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders

The American journal of gastroenterology, 2020-12, Vol.115 (Suppl 1), p.S7-S8 [Peer Reviewed Journal]

2020 by The American College of Gastroenterology ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/01.ajg.0000722908.13222.64 ;PMID: 33566502

Full text available

Citations Cited by
14
S3207 Vanishing Tacrolimus Syndrome
S3207 Vanishing Tacrolimus Syndrome
Material Type:
Article 		Add to My Research

S3207 Vanishing Tacrolimus Syndrome

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e2051-e2051 [Peer Reviewed Journal]

2022 by The American College of Gastroenterology ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/01.ajg.0000869468.28475.27

Full text available

Citations Cited by
15
S3229 A Case of Cholestatic Drug-Induced Liver Injury After Ashwagandha Root Supplementation
S3229 A Case of Cholestatic Drug-Induced Liver Injury After Ashwagandha Root Supplementation
Material Type:
Article 		Add to My Research

S3229 A Case of Cholestatic Drug-Induced Liver Injury After Ashwagandha Root Supplementation

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e2062-e2062 [Peer Reviewed Journal]

2022 by The American College of Gastroenterology ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/01.ajg.0000869556.43701.6b

Full text available

Citations Cited by
16
0500 Evaluation of the Human Abuse Potential of Single Oral Doses of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors
0500 Evaluation of the Human Abuse Potential of Single Oral Doses of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors
Material Type:
Article 		Add to My Research

0500 Evaluation of the Human Abuse Potential of Single Oral Doses of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors

Sleep (New York, N.Y.), 2020-05, Vol.43 (Supplement_1), p.A191-A192 [Peer Reviewed Journal]

Sleep Research Society 2020. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com. 2020 ;Sleep Research Society 2020. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com. ;ISSN: 0161-8105 ;EISSN: 1550-9109 ;DOI: 10.1093/sleep/zsaa056.497

Full text available

Citations Cited by
17
S727 Adalimumab Serum Levels in Relation to World Health Organization Standardization and Immunization in Clinical Gastroenterology Practice
S727 Adalimumab Serum Levels in Relation to World Health Organization Standardization and Immunization in Clinical Gastroenterology Practice
Material Type:
Article 		Add to My Research

S727 Adalimumab Serum Levels in Relation to World Health Organization Standardization and Immunization in Clinical Gastroenterology Practice

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S332-S332 [Peer Reviewed Journal]

2021 by The American College of Gastroenterology ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/01.ajg.0000776440.01416.18

Full text available

Citations Cited by
18
S871 Patients Hospitalized With Acute Severe Ulcerative Colitis Undergoing Colectomy Within Three Months Have Lower Oral Cyclosporine Levels
S871 Patients Hospitalized With Acute Severe Ulcerative Colitis Undergoing Colectomy Within Three Months Have Lower Oral Cyclosporine Levels
Material Type:
Article 		Add to My Research

S871 Patients Hospitalized With Acute Severe Ulcerative Colitis Undergoing Colectomy Within Three Months Have Lower Oral Cyclosporine Levels

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S407-S408 [Peer Reviewed Journal]

2021 by The American College of Gastroenterology ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/01.ajg.0000777016.05075.fa

Full text available

Citations Cited by
19
S357 Esophageal Lichen Planus: The Efficacy and Safety of Tacrolimus in Reducing Inflammation and Need for Dilation
S357 Esophageal Lichen Planus: The Efficacy and Safety of Tacrolimus in Reducing Inflammation and Need for Dilation
Material Type:
Article 		Add to My Research

S357 Esophageal Lichen Planus: The Efficacy and Safety of Tacrolimus in Reducing Inflammation and Need for Dilation

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S155-S155 [Peer Reviewed Journal]

2021 by The American College of Gastroenterology ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/01.ajg.0000773900.08059.b1

Full text available

Citations Cited by
20
Pazopanib in the treatment of advanced solitary fibrous tumour – Authors' reply
Pazopanib in the treatment of advanced solitary fibrous tumour – Authors' reply
Material Type:
Article 		Add to My Research

Pazopanib in the treatment of advanced solitary fibrous tumour – Authors' reply

The lancet oncology, 2019-03, Vol.20 (3), p.e128-e128 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright Elsevier Limited Mar 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30080-4 ;PMID: 30842052

Full text available

Citations Cited by

Results 1 - 20 of 133,555  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (106,640)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1962  (68)
  2. 1962 To 1976  (227)
  3. 1977 To 1991  (1,329)
  4. 1992 To 2007  (10,750)
  5. After 2007  (121,209)
  6. More options open sub menu

Subject 

  1. Drug Dosages  (131,861)
  2. Science & Technology  (92,157)
  3. Life Sciences & Biomedicine  (82,925)
  4. Humans  (42,849)
  5. Patients  (39,870)
  6. Male  (21,663)
  7. Female  (21,245)
  8. Clinical Trials  (18,277)
  9. Pharmacology & Pharmacy  (17,318)
  10. Studies  (15,581)
  11. Medicine  (15,472)
  12. Cancer Therapies  (14,895)
  13. Drug Therapy  (14,701)
  14. Animals  (14,469)
  15. Adult  (12,857)
  16. General & Internal Medicine  (12,835)
  17. Health Aspects  (12,607)
  18. Middle Aged  (12,541)
  19. Chemotherapy  (12,224)
  20. Care And Treatment  (12,206)
  21. More options open sub menu

Language 

  1. English  (133,255)
  2. Japanese  (7,594)
  3. Portuguese  (386)
  4. French  (272)
  5. Turkish  (124)
  6. Chinese  (117)
  7. Norwegian  (104)
  8. Spanish  (92)
  9. Dutch  (60)
  10. German  (59)
  11. Polish  (45)
  12. Russian  (35)
  13. Italian  (20)
  14. Ukrainian  (8)
  15. Slovenian  (8)
  16. Czech  (7)
  17. Swedish  (7)
  18. Slovak  (5)
  19. Persian  (5)
  20. Korean  (4)
  21. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait